Drugs that control monoamine signaling may be effective in treating ATP1A3 mutation-related neurological diseases, where it has been hypothesized that high monoamine levels are a consequence of seizure activity rather than a cause (Ikeda et al., 2017). Here, ATP1A3 is linked to nervous system disorder.